BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 9393627)

  • 21. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
    Klinger M; Brandl C; Zugmaier G; Hijazi Y; Bargou RC; Topp MS; Gökbuget N; Neumann S; Goebeler M; Viardot A; Stelljes M; Brüggemann M; Hoelzer D; Degenhard E; Nagorsen D; Baeuerle PA; Wolf A; Kufer P
    Blood; 2012 Jun; 119(26):6226-33. PubMed ID: 22592608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
    Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
    MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
    Brandl C; Haas C; d'Argouges S; Fisch T; Kufer P; Brischwein K; Prang N; Bargou R; Suzich J; Baeuerle PA; Hofmeister R
    Cancer Immunol Immunother; 2007 Oct; 56(10):1551-63. PubMed ID: 17310380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
    Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
    Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency.
    Punnonen J; Kainulainen L; Ruuskanen O; Nikoskelainen J; Arvilommi H
    Scand J Immunol; 1997 Feb; 45(2):203-12. PubMed ID: 9042433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.
    Smans KA; Hoylaerts MF; De Broe ME
    Cancer Immunol Immunother; 1994 Jan; 38(1):43-52. PubMed ID: 8299118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
    Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
    Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.
    Dettmar K; Seitz-Merwald I; Lindemann C; Schroeder P; Seimetz D; Atz J
    Clin Transl Oncol; 2012 May; 14(5):376-81. PubMed ID: 22551544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.
    Anderson PM; Crist W; Hasz D; Carroll AJ; Myers DE; Uckun FM
    Blood; 1992 Dec; 80(11):2826-34. PubMed ID: 1280479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
    Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
    Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
    Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
    Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
    Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
    J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
    Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
    Duell J; Lukic DS; Karg M; Reusch U; Koch J; Zhukovsky EA; Rajkovic E; Treder M; Rasche L; Eisele F; Einsele H; Topp MS
    J Immunother; 2019 Jun; 42(5):180-188. PubMed ID: 31090657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.